Publications by authors named "Anouk Kesselring"
Article Synopsis
- The study examined the link between immunodeficiency and non-AIDS diseases in patients with viral suppression on antiretroviral therapy, focusing on treatment interruptions and viremia levels.
- Researchers analyzed data from 6,440 patients in the Dutch ATHENA cohort, measuring the incidence of serious non-AIDS diseases like cardiovascular issues, chronic renal failure, and liver conditions.
- Findings indicated that lower CD4 counts correlate with higher non-AIDS disease risk, while high-level viremia was significantly linked only to cardiovascular disease, but not to treatment interruptions or low-level viremia effects.
Article Synopsis
- Scientists looked at how well HIV patients did after taking medicine for 2 years and how their immune system got better.
- They found that patients with lower immune cell counts after treatment had a higher risk of serious health problems like AIDS and heart issues.
- The study suggests that starting treatment earlier, especially for older patients, can help them have a better chance of staying healthy.
Background: The aim of this study was to investigate the association between immunodeficiency, viremia, and non-AIDS-defining malignancies (NADM).
Methods: Patients starting combination antiretroviral therapy (cART) as of 1 January 1996 were selected from the AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. In Cox models, risk factors for NADM were investigated.
Background: We investigated differences in immune restoration and onset of new AIDS-defining events on combination antiretroviral therapy (cART) among HIV type-1 (HIV-1)-infected patients of different regional origin now living in the Netherlands.
Methods: Treatment-naive adults reaching plasma viral load (pVL)<400 copies/ml within 9 months of starting cART were selected from the Netherlands ATHENA cohort. CD4(+) T-cell response on cART was determined over 7 years using mixed models.
Background: This collaboration of seven observational clinical cohorts investigated risk factors for treatment-limiting toxicities in both antiretroviral-naive and experienced patients starting nevirapine-based combination antiretroviral therapy (NVPc).
Methods: Patients starting NVPc after 1 January 1998 were included. CD4 cell count at starting NVPc was classified as high (>400/microl/>250/microl for men/women, respectively) or low.
Background: Recommendations that nevirapine (NVP) should be avoided in female individuals with CD4 cell counts >250 cells/microL and in male individuals with CD4 cell counts >400 cells/microL are based on findings in treatment-naive patients. It is unclear whether these guidelines also apply to treatment-experienced patients switching to NVP-based combination therapy.
Methods: Patients in the ATHENA cohort study who had used NVP-based combination therapy were included.
Objective: CD4 cell count changes in therapy-naive patients were investigated during 7 years of highly active antiretroviral therapy (HAART) in an observational cohort.
Methods: Three endpoints were studied: (1) time to >or=800 CD4 cells/mm in 5299 therapy-naive patients starting HAART, (2) CD4 cell count changes during 7 years of uninterrupted HAART in a subset of 544 patients, and (3) reaching a plateau in CD4 cell restoration after 5 years of HAART in 366 virologically suppressed patients.
Results: Among patients with <50, 50 to 200, 200 to 350, 350 to 500, and >or=500 CD4 cells/mm at baseline, respectively, 20%, 26%, 46%, 73%, and 87% reached >or=800 CD4 cells/mm within 7 years of starting HAART.